BackShenzhen Hepalink Pharmaceutical Group , Ltd. Overview

Shenzhen Hepalink Pharmaceutical Group , Ltd. Total Liabilities

Latest total liabilities for SHEZF: $4.5B.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$4.49B
↓ 10.61% YoYΔ $-532.89M vs prior year quarter

Peer trimmed avg / median

Loading

Shenzhen Hepalink Pharmaceutical Group , Ltd. Total Liabilities History

Loading

Shenzhen Hepalink Pharmaceutical Group , Ltd. vs. peers: Total Liabilities Comparison

Loading

Shenzhen Hepalink Pharmaceutical Group , Ltd. Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Shenzhen Hepalink Pharmaceutical Group , Ltd. (SHEZF) FAQ

As of the most recent data (June 2026), SHEZF shows a total liabilities of $4.5B. That compares with $5B in the prior-year period — down 10.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SHEZF's total liabilities is now $4.5B (was $5B) — a 10.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Shenzhen Hepalink Pharmaceutical Group , Ltd. is outperforming or lagging.

Tracking SHEZF's total liabilities over time shows whether Shenzhen Hepalink Pharmaceutical Group , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $4.5B That compares with $5B in the prior-year period — down 10.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Shenzhen Hepalink Pharmaceutical Group , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $4.5B) with ownership activity and broader fundamentals.